Stay updated on Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.

Latest updates to the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedEnrollment is closed to new participants, reflecting a recruitment-status update on the study page. The record has been updated to include the latest revision tag v3.6.0.SummaryDifference0.4%

- Check15 days agoChange DetectedNew revision v3.5.5 was added to the revision history, replacing the previous v3.5.4. This update signifies an administrative change to the page's version record rather than content changes.SummaryDifference0.1%

- Check37 days agoChange DetectedThe page's revision label updates from v3.5.3 to v3.5.4, indicating a newer release of the page's interface. This is a UI/system update rather than substantive changes to the study record or its data.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page’s ClinicalTrials.gov interface revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site tooling update rather than a change to the trial’s record data.SummaryDifference0.1%

- Check66 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the history.SummaryDifference0.1%

- Check94 days agoChange DetectedThe page history now shows a new revision labeled v3.5.0, while the previous revision v3.4.3 is no longer listed.SummaryDifference0.1%

Stay in the know with updates to Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.